HALO
HALO
NASDAQ · Biotechnology

Halozyme Therapeutics Inc

$64.12
-1.07 (-1.64%)
As of May 9, 1:11 AM ET ·
Analyst Consensus
Buy
15
Analysts
High
Coverage
Buy 11 73%
Hold 3 20%
Sell 1 7%
Price Target
Analyst Price Target -67.2% upside
Low Target $15.29
Average Target $21.02
High Target $24.22
Current Price $64.12
Current
$64.12
Target
$21.02
$15.29 $21.02 avg $24.22
Scenario Analysis
Bear Case
$15.29
-76.2%
Low target
Base Case
$21.02
-67.2%
Avg target
Bull Case
$24.22
+-62.2%
High target
Risk/Reward
0.8x
Unfavorable
Price in Context
52-Week High
$82.22
-22.0% from high
52-Week Low
$47.50
+35.0% from low
50-Day SMA
$71.23
-10.0% vs SMA
200-Day SMA
$65.75
-2.5% vs SMA
RSI (14)
47.6
Neutral
Target vs 52W High
$21.02
-74.4% vs high
Next Earnings Report
May 12, 2026
2d
until earnings
EPS Est: $1.56
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 72% $257.58 +27.8%
AMGN
Amgen Inc
Hold 43 49% $190.87 -42.5%
GILD
Gilead Sciences Inc
Strong Buy 39 79% $362.68 +176.2%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 +2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 38 79% $76.80 -89.3%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -65.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -19.5%
INSM
Insmed Inc
Strong Buy 26 96% $143.40 +41.5%